FOLH1 and neoplasm: Previous studies investigating high-risk subgroups—such as patients with extensive tumor burden and visceral metastases—have demonstrated lower response rates and shorter survival outcomes following PSMA-RLT, with reported median overall survival ranging between 6 and 11 months in these populations [23, 24].